Summary
This prediction ended on 22.01.19 with a price of €5.19. Massive losses of -75.18% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Aptinyx | - | - | - | - |
| iShares Core DAX® | -0.372% | 5.236% | 16.908% | 16.016% |
| iShares Nasdaq 100 | -1.950% | 1.680% | 19.890% | 31.832% |
| iShares Nikkei 225® | -1.690% | 7.286% | 12.202% | 3.400% |
| iShares S&P 500 | -0.399% | 2.379% | 20.975% | 36.224% |
Comments by melinda for this prediction
In the thread Aptinyx diskutieren
SecteurProduits pharmaceutiques
Discovers and develops therapies for challenging disorders
Aptinyx Inc. is a clinical stage biopharmaceutical company.
It is discovering and developing transformative therapies for disorders of the brain and nervous system.
The company was founded by Norbert G. Riedel and Joseph R. Moskal and is headquartered in Evanston, IL.
Aptinyx Inc. is a clinical stage biopharmaceutical company.
It is discovering and developing transformative therapies for disorders of the brain and nervous system.
The company was founded by Norbert G. Riedel and Joseph R. Moskal and is headquartered in Evanston, IL.
Nombre d'employés : 60 personnes.
(Vom Mitglied beendet)